BHCN.MX - Bausch Health Companies Inc.
| Previous close | 140.18 |
| Open | 0.00 |
| Bid | 120.00 x 0 |
| Ask | 161.00 x 0 |
| Day's range | 140.18 - 140.18 |
| 52-week range | 90.80 - 185.00 |
| Volume | |
| Avg. volume | 2,908 |
| Market cap | 49.878B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -22.93 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireOraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover Your Bases campaign includes educational content about the disease and encourages patients to talk to their dentist about comprehensive treatment options. The campaign launch is timed to Oral Health Month recognized throughout June a
ZacksBausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
ZacksBausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksBausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksBausch + Lomb (BLCO) Q1 Earnings Lag Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 0.3x Bausch Health Companies Inc. ( NYSE:BHC ) may be sending very bullish...
Simply Wall St.Lacklustre Performance Is Driving Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
With a price-to-sales (or "P/S") ratio of 1.5x Bausch + Lomb Corporation ( NYSE:BLCO ) may be sending very bullish...
ZacksBausch Health (BHC) Q4 Earnings and Revenues Top Estimates
Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksPerion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
- Simply Wall St.
Bausch + Lomb Full Year 2022 Earnings: EPS Misses Expectations
Bausch + Lomb ( NYSE:BLCO ) Full Year 2022 Results Key Financial Results Revenue: US$3.77b (flat on FY 2021). Net...
ZacksDrug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
- Simply Wall St.
Positive week for Bausch Health Companies Inc. (NYSE:BHC) institutional investors who lost 60% over the past year
A look at the shareholders of Bausch Health Companies Inc. ( NYSE:BHC ) can tell us which group is most powerful. With...
ZacksBausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ZacksNew Strong Sell Stocks for December 9th
ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.
- Simply Wall St.
Is There An Opportunity With Bausch + Lomb Corporation's (NYSE:BLCO) 45% Undervaluation?
How far off is Bausch + Lomb Corporation ( NYSE:BLCO ) from its intrinsic value? Using the most recent financial data...
PR NewswireSALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION
Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today released the Salix Liver Health Annual Trends Report, Second Edition with the latest information on chronic liver disease (CLD) care and findings that include a continued rise in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirrhosis and its complicati
PR NewswireSeasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") is continuing its commitment to improving lives with the announcement of modifications within the Tabular Index, specifically for the prevention and treatment of SAD from the Centers for Medicare & Medicaid Services (CMS). Now, all appropriate codes have been combined into a bundle for SAD which allows healthcare professionals to further clarify a diagnosis in an easy-to-understand index tab and send all diagnoses for SAD to one simp
- PR Newswire
SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis
- PR Newswire
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the final results and expiration of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents (the "Consent Solicitations" and, together with the Exc
Motley FoolWhy Bausch Health Stock Is Jumping Today
Shares of Bausch Health Company (NYSE: BHC) were jumping 4.4% at 10:54 a.m. ET on Wednesday after rising as much as 11.8% earlier in the day. Bausch Health announced on Aug. 30 that it planned to conduct these exchange offers. On Sept. 8, Bausch released a clarification about some of the provisions pertaining to its exchange offers.
- PR Newswire
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the results to date of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors (as defined below), the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents
- Simply Wall St.
Great week for Bausch Health Companies Inc. (NYSE:BHC) institutional investors after losing 74% over the previous year
If you want to know who really controls Bausch Health Companies Inc. ( NYSE:BHC ), then you'll have to look at the...
- PR Newswire
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("the Company"), and its gastroenterology business Salix Pharmaceuticals, today responded to the U.S. Food and Drug Administration's (FDA) tentative approval of the Norwich Pharmaceuticals rifaximin 200 mg product.
- PR Newswire
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") clarified today certain provisions related to its previously announced offers (the "Exchange Offers") to exchange the existing senior notes (the "Existing Senior Notes") for new secured notes (the "New Secured Notes") and related solicitation of consent (the "Consent Solicitation") pursuant to the terms described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated Aug. 30, 2022 (the "Exchange Offer Memorandum").
ZacksWhy Is Bausch (BHC) Up 23% Since Last Earnings Report?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.